We searched the Cochrane Library and MEDLINE with the term “gout” for articles published in English between Aug 1, 2010, and Jan 31, 2016. We largely selected publications from the past 5 years, but did not exclude commonly referenced and highly regarded older publications. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Review articles and book chapters are cited to provide readers with more details and more references
SeminarGout
Introduction
Gout is a common and treatable form of inflammatory arthritis that affects almost 4% of adults in the USA.1 The central pathological feature of gout is chronic deposition of monosodium urate crystals, which form in the presence of increased urate concentrations.2 The clinical features of gout occur as a result of the inflammatory response to monosodium urate crystals, and treatment strategies that achieve crystal dissolution are central to effective gout management.3 In the past decade, major progress has been made in understanding of the pathogenesis, impact, diagnostic approaches to, and treatment of this disorder. In this Seminar, we provide a summary of these advances with a focus on clinical management of gout.
Section snippets
Hyperuricaemia
The progression of gout can be defined by four pathophysiological stages: hyperuricaemia without evidence of monosodium urate crystal deposition or gout, crystal deposition without symptomatic gout, crystal deposition with acute gout flares, and advanced gout characterised by tophi, chronic gouty arthritis, and radiographic erosions.4 Progression from one stage to the next is not inevitable.
Pathological hyperuricaemia has been defined as the serum urate concentration (408 μmol/L [6·8 mg/dL])
Incidence and prevalence
In UK and US studies, the incidence of gout varies from 0·30 per 1000 person-years in the 1970s, to 2·68 per 1000 person-years in the 2000s.20 In western developed countries, contemporary prevalence of gout is 3–6% in men and 1–2% in women.20 Prevalence steadily increases with age, but plateaus after 70 years of age.20 Lower prevalences have been reported in developing countries—typically less than 1%.20, 21 Differences in health-care systems or case ascertainment might account for some of
Presentation
Typically, gout presents for the first time as an acute episode of inflammation (flare) affecting the foot or ankle.18 The first flare occurs after an asymptomatic period of hyperuricaemia. It is self-limiting during 1–2 weeks, with complete resolution in signs and symptoms of joint inflammation during the so-called intercritical period. If hyperuricaemia persists, recurrent flares can occur, which become increasingly frequent and prolonged and affect many joints (polyarticular flares),
Principles of management
Gout management includes rapid treatment of acute flares and effective long-term management (table 2).3, 99, 100, 101 The central strategy for long-term management is reduction of serum urate to a concentration that achieves dissolution of monosodium urate crystals. According to the 2012 American College of Rheumatology guidelines, urate-lowering therapy is indicated for those with recurrent gout flares (>1 flare a year), tophi, stage 2 or worse chronic kidney disease, or kidney stones (table 2
Controversies and uncertainties
Although the central cause of gout is well known and effective treatments are available, many uncertainties remain and understanding about pathogenesis is incomplete (panel 2). For example, why some individuals with hyperuricaemia develop monosodium urate crystal deposition and others do not is unknown. Why monosodium urate crystals preferentially deposit at specific sites and why deposited crystals can be present in the joint without clinically apparent inflammation is also unclear. The causal
Conclusion
Despite major progress in the understanding of pathogenesis and therapeutic advances, the prevalence of gout is increasing and many patients have poorly controlled disease. Gout is a treatable disease and the strategy of long-term lowering of serum urate concentrations is highly effective in removing monosodium urate crystals. Implementation of this strategy necessitates focused attention to prevent the serious consequences of this disease.
Search strategy and selection criteria
References (153)
- et al.
Causal assessment of serum urate levels in cardiometabolic diseases through a mendelian randomization study
J Am Coll Cardiol
(2016) - et al.
Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function
Kidney Int
(2014) - et al.
A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study
Am J Kidney Dis
(2015) - et al.
Gout and the risk of dementia: a nationwide population-based cohort study
Arthritis Res Ther
(2015) - et al.
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study
Am J Med
(1987) - et al.
Alcohol consumption as a trigger of recurrent gout attacks
Am J Med
(2006) - et al.
The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi
Semin Arthritis Rheum
(2012) - et al.
Synovial fluid analysis
Best Pract Res Clin Rheumatol
(2005) - et al.
“Crystal clear”-sonographic assessment of gout and calcium pyrophosphate deposition disease
Semin Arthritis Rheum
(2006) - et al.
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008
Arthritis Rheum
(2011)